Your email was delivered. It was placed in the inbox. And the physician still never saw it. Between send and action there are four checkpoints: server acceptance, inbox placement, AI prioritization, and reader attention. Deliverability reporting covers the first two and goes silent on the rest. Pharma feels this shift hardest. The HCP inbox is usually a highly monitored corporate account, where filtering is strict and sender history is unforgiving. And rare disease audiences are small enough that a handful of complaints can compromise reach across the entire list. There is no volume to hide behind. Our new white paper, The Inbox Frontier, maps all four checkpoints: what the models weigh, how corporate tenants filter, and how to measure attention past the delivery report. Read it at vist.ly/5j6aw Delivered tells you the email arrived. Seen tells you it mattered. #PharmaMarketing #EmailDeliverability #HCPEngagement #HCPMarketing"

Brand Planning Urgency: 2027 Is Being Decided Now The 2027 brand plan is being written right now. Not in January. Now. Between August and October, tactical plans get drafted, budgets get modeled, and agency scopes get locked. By the time the new year starts, those decisions are already a quarter old. Here is what that timing really means: whatever does not make the plan this fall mostly does not happen next year. And in a market where AI is rewriting how HCPs search, learn, and decide, sitting out a cycle does not cost you one year. It costs you two, because 2028 gets planned with the same blind spots. If there is a capability you have been meaning to evaluate, the evaluation window is open now. It closes quietly, sometime around October, without an announcement. Learn more: vist.ly/5j6av #BrandPlanning #PharmaMarketing #PharmaCommercial #HCPMarketing

Your HCP target list has an expiration date. The healthcare market doesn’t stand still. NPs and PAs are taking on greater roles in patient care. Prescribing behavior changes. HCPs change specialties, practices and care settings. New clinicians enter the treatment journey while others become less relevant. But many target lists remain largely unchanged from one planning cycle to the next. That creates a growing gap between who your brand planned to reach and who is actually influencing treatment today. At SloganTech, we believe HCP targeting should be dynamic. Start with deterministic NPI-level identity. Layer in current claims and prescribing behavior. Understand which HCPs are seeing relevant patients, how their role in the treatment journey is changing and where new opportunities are emerging. Then continuously use those signals to refine who matters and how they should be engaged. Because the goal isn’t to build the perfect target list once. It’s to build HCP intelligence that evolves with the market. The market moved. The prescribing moved. Did your target list move with them? See how your HCP universe has changed at vist.ly/5j6c5 #HCPMarketing #BrandPlanning #PharmaMarketing #OmnichannelMarketing

For rare disease and pediatric brands, marketing precision isn't optional. Every HCP matters. Every touchpoint counts. Every campaign should connect to measurable prescription impact. That conviction shaped our new brand. And it shapes every partnership we build. Discover what orchestrated pharma marketing can unlock for your brand: vist.ly/5j6c9

What we tell every first-time rare disease brand manager. Your market is not small. It is specific. Learn the diagnostic journey before the media plan. The prescriber is often the third clinician to see the patient. Your Target List is a list of people, not a segment. At a few hundred names, you can know them. Reach is not a milestone. Ask what the physicians you reached did next. Insist on a control group. Ensure messaging drives clear, measurable action. #PharmaMarketing #HCPMarketing #SloganTech #RareDisease #Leadership Learn More: vist.ly/5j6ca